After illness, the boundaries of daily life contract almost imperceptibly. A trip that once felt routine — like driving to ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
Southern California Pulmonary and Sleep Disorders Medical Center announced the expanded availability of Bongo Rx, an ...
Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and ...
OSTEOPATHIC manipulative treatment (OMT) may improve pulmonary function in asthma, though current evidence remains limited ...
Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.
For children with single-ventricle disease, death or major morbidity occurs in 87%, and shunt type impact varies.
United News of Bangladesh on MSN
Air quality in Dhaka 'moderate' as city ranks 10th globally
Dhaka, March 20 -- Dhaka, the densely populated capital of Bangladesh, ranked 10th among the world's most polluted cities on Friday morning, recording an Air Quality Index (AQI) of 126 at 11:15 am.
Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results